Late Breaker abstract list
Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with nonalcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)
Stephen A. HARRISON, United States

Lack of reliability of liver biopsies in nonalcoholic steatohepatitis (NASH) clinical trials - potential implications for developing new therapies for NASH
Stephen A. HARRISON, United States

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Manal ABDELMALEK, United States

Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400mg daily added to a nucleoside in HBV EAg negative patients
Kosh AGARWAL, United Kingdom

Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
Kosh AGARWAL, United Kingdom

Wide variations in liver transplantation (LT) policies across Europe for patients with acute on chronic liver failure (ACLF) despite excellent post-LT survival: Results of a CLIF/ELITA collaborative study
Luca Saverio BELLI, Italy

Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study
Gregory DORE, Australia

faecal microbiota transplantation reduces pathogenic burden and is anti-inflammatory in patients with advanced cirrhosis
Lindsey EDWARDS, United Kingdom

The impact on mortality of a national hepatitis C elimination program, Georgia, 2015-2019
Lia GVINJILIA, Georgia

Bariatric surgery is not associated with a reduction in risk of severe liver disease in comparison to standard obesity treatment in 3,922 subjects
Hannes HAGSTRÖM, Sweden

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data
Harry JANSSEN, Canada

A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study.
Christopher KOH, United States
Proof-of-concept use of machine learning to predict tumor recurrence of early-stage hepatocellular carcinoma before therapy using baseline magnetic resonance imaging
Ahmet Said KÜCÜKKAYA, United States

Hepatocyte-specific deficiency of sphingosine kinase 1 exacerbates acetaminophen-induced liver injury
Tian LAN, China

MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study
Eric LAWITZ, United States

BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial
Eric LAWITZ, United States

JKB-122 in subjects with non-alcoholic fatty liver disease (NAFLD): a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study
Sheng-Hung LIU, Taiwan

Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study
Rohit LOOMBA, United States

CX3CL1/CXCR1 axis recruits regulatory macrophages to promote tumor recurrence of intrahepatic cholangiocarcinoma after curative surgery
Kwan MAN, Hong Kong

Serum-based Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant fibrosis
Mazen NOUREDDIN, United States

Screening for Non-alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Economical Analysis
Mazen NOUREDDIN, United States

CHESS criteria for the screening of varices in patients with compensated advanced chronic liver disease: a multicenter study
Xiaolong QI, China

Post-fecal microbiota transplant taxa correlate with 3-month survival in severe alcoholic hepatitis patients
Shvetank SHARMA, India

A novel immunoregulatory role for complement receptor C3AR1 in fibrosing cholangiopathies of biliary atresia and primary sclerosing cholangitis
Pranavkumar SHIVAKUMAR, United States

Resolution of nonalcoholic steatohepatitis and hepatic fibrosis by sodium glucose transporter-2 inhibitor, ipragliflozin; a multicenter randomized controlled trial
Hirokazu TAKAHASHI, Japan
Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients
Marianne TUEFFERD, Belgium

Noninvasive point-of-care 13C-Methacetin Breath Test (MBT) predicts risk of clinical deterioration independently of currently used prognostic indicators in patients with decompensated NASH cirrhosis
John VIERLING, United States

Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal microbiota Transplantation in advanced cirrhosis
Charlotte WOODHOUSE, United Kingdom

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
Man-Fung YUEN, Hong Kong

Machine Learning Identifies Histologic Features Associated with Regression of Cirrhosis in Treatment for Chronic Hepatitis B
Oscar ZEVALLOS, United States

long-term survival of repeat hepatic resection and radiofrequency ablation for patients with recurrent hepatocellular carcinoma: a multicentric study
Jian-Hong ZHONG, China

Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies
Andrew VAILLANT, Canada